WGU D027 Advanced
Pathopharmacological Foundations OA
Exam 2026/2027 Complete Test Bank: 150
Questions with Answers and Detailed
Rationales | Graded A+
Instructions
This comprehensive test bank contains 150 multiple-choice questions designed to prepare you
for the WGU D027 Advanced Pathopharmacological Foundations Objective Assessment (OA).
Questions are organized by key content domains and include verified correct answers with
detailed rationales explaining the pathophysiology and pharmacological principles tested .
SECTION 1: CELLULAR REGULATION AND CANCER BIOLOGY (Questions 1-20)
Question 1
A patient with a history of smoking presents with a persistent cough, weight loss, and
hemoptysis. A lung biopsy reveals malignant cells. Which cellular characteristic is most
consistent with malignancy?
A) Increased apoptosis rate
B) Contact inhibition
C) Loss of differentiation (anaplasia)
D) Decreased mitotic rate
Correct Answer: C. Loss of differentiation (anaplasia)
Rationale: Anaplasia refers to loss of cellular differentiation, a hallmark of malignant cells.
Malignant cells exhibit high mitotic rates (not decreased, D), loss of contact inhibition (not
maintained, B), and reduced apoptosis (not increased, A). These features allow uncontrolled
growth and invasion .
,Question 2
A woman with a BRCA1 gene mutation asks about her risk for breast cancer. What is the
nurse's best response?
A) "BRCA1 mutation is not associated with breast cancer risk."
B) "Women with BRCA1 mutations have a 50-80% lifetime risk of breast cancer."
C) "BRCA1 mutations only increase ovarian cancer risk, not breast cancer."
D) "BRCA1 mutations guarantee that you will develop breast cancer."
Correct Answer: B. "Women with BRCA1 mutations have a 50-80% lifetime risk of breast
cancer."
Rationale: BRCA1 and BRCA2 are tumor suppressor genes. Mutations significantly increase
breast cancer risk (50-80% lifetime) and ovarian cancer risk (20-40%). The mutations do not
guarantee cancer development (D is false), as other factors influence penetrance .
Question 3
During carcinogenesis, the process by which a normal cell acquires genetic mutations leading to
malignant transformation is called:
A) Apoptosis
B) Metastasis
C) Initiation-promotion-progression
D) Angiogenesis
Correct Answer: C. Initiation-promotion-progression
Rationale: Carcinogenesis involves three stages: initiation (DNA damage by carcinogen),
promotion (proliferation of initiated cells), and progression (acquisition of invasive/metastatic
capabilities). Apoptosis (A) is programmed cell death; metastasis (B) is spread to distant sites;
angiogenesis (D) is new blood vessel formation .
Question 4
A patient receiving chemotherapy develops neutropenia. Which assessment finding is most
concerning?
A) Temperature of 38.3°C (101.0°F)
B) Fatigue
,C) Nausea
D) Alopecia
Correct Answer: A. Temperature of 38.3°C (101.0°F)
Rationale: Fever in a neutropenic patient (febrile neutropenia) is a medical emergency indicating
possible sepsis. Neutropenic patients have impaired inflammatory response and may not show
typical signs of infection. Fever is the earliest sign requiring immediate evaluation and
antibiotics. Fatigue (B), nausea (C), and alopecia (D) are common but not life-threatening .
Question 5
A patient with breast cancer is receiving trastuzumab (Herceptin). This medication is most
effective in patients whose tumors are:
A) Estrogen receptor-positive
B) HER2/neu-positive
C) Triple-negative
D) Progesterone receptor-positive
Correct Answer: B. HER2/neu-positive
Rationale: Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor. It is
effective only in tumors that overexpress HER2 (HER2-positive breast cancer). Testing for
HER2 status is required before prescribing. Estrogen receptor-positive tumors are treated with
hormonal therapy (tamoxifen, aromatase inhibitors) .
Question 6
A patient receiving cisplatin reports tinnitus. What is the priority nursing action?
A) Administer acetaminophen for pain
B) Notify the provider immediately
C) Administer IV fluids to enhance excretion
D) Document the finding and continue monitoring
Correct Answer: B. Notify the provider immediately
Rationale: Cisplatin causes ototoxicity (tinnitus, hearing loss), which can be irreversible. Tinnitus
is an early sign of ototoxicity; prompt reporting may allow dose adjustment or discontinuation.
Administering fluids (C) may only help with nephrotoxicity, not ototoxicity. Documentation alone
(D) is insufficient without notifying the provider .
, Question 7
Tumor lysis syndrome (TLS) is a metabolic emergency most commonly associated with
treatment of which malignancies?
A) Solid tumors (breast, lung, colon)
B) Leukemia and lymphoma
C) Brain tumors
D) Melanoma
Correct Answer: B. Leukemia and lymphoma
Rationale: TLS occurs when tumor cells lyse rapidly after chemotherapy, releasing intracellular
contents into the bloodstream. It is most common in highly proliferative, chemotherapy-sensitive
tumors (acute leukemias, high-grade lymphomas, Burkitt lymphoma). TLS causes
hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, acute kidney injury, and
arrhythmias .
Question 8
The nurse is teaching a patient about colony-stimulating factors (filgrastim, pegfilgrastim). Which
statement indicates correct understanding?
A) "This medication will increase my platelet count."
B) "It will stimulate my bone marrow to produce more white blood cells."
C) "I will take this medication orally at home."
D) "I can expect immediate results after the first dose."
Correct Answer: B. "It will stimulate my bone marrow to produce more white blood cells."
Rationale: Filgrastim and pegfilgrastim are granulocyte colony-stimulating factors (G-CSF) that
stimulate neutrophil production. They are used to prevent or treat neutropenia. They do not
increase platelets (A); thrombopoietin agonists do that. They are given subcutaneously (not oral,
C), and results take several days (D) .
Question 9
Which statement accurately describes the role of tumor suppressor genes in carcinogenesis?
A) They promote cell division when mutated
Pathopharmacological Foundations OA
Exam 2026/2027 Complete Test Bank: 150
Questions with Answers and Detailed
Rationales | Graded A+
Instructions
This comprehensive test bank contains 150 multiple-choice questions designed to prepare you
for the WGU D027 Advanced Pathopharmacological Foundations Objective Assessment (OA).
Questions are organized by key content domains and include verified correct answers with
detailed rationales explaining the pathophysiology and pharmacological principles tested .
SECTION 1: CELLULAR REGULATION AND CANCER BIOLOGY (Questions 1-20)
Question 1
A patient with a history of smoking presents with a persistent cough, weight loss, and
hemoptysis. A lung biopsy reveals malignant cells. Which cellular characteristic is most
consistent with malignancy?
A) Increased apoptosis rate
B) Contact inhibition
C) Loss of differentiation (anaplasia)
D) Decreased mitotic rate
Correct Answer: C. Loss of differentiation (anaplasia)
Rationale: Anaplasia refers to loss of cellular differentiation, a hallmark of malignant cells.
Malignant cells exhibit high mitotic rates (not decreased, D), loss of contact inhibition (not
maintained, B), and reduced apoptosis (not increased, A). These features allow uncontrolled
growth and invasion .
,Question 2
A woman with a BRCA1 gene mutation asks about her risk for breast cancer. What is the
nurse's best response?
A) "BRCA1 mutation is not associated with breast cancer risk."
B) "Women with BRCA1 mutations have a 50-80% lifetime risk of breast cancer."
C) "BRCA1 mutations only increase ovarian cancer risk, not breast cancer."
D) "BRCA1 mutations guarantee that you will develop breast cancer."
Correct Answer: B. "Women with BRCA1 mutations have a 50-80% lifetime risk of breast
cancer."
Rationale: BRCA1 and BRCA2 are tumor suppressor genes. Mutations significantly increase
breast cancer risk (50-80% lifetime) and ovarian cancer risk (20-40%). The mutations do not
guarantee cancer development (D is false), as other factors influence penetrance .
Question 3
During carcinogenesis, the process by which a normal cell acquires genetic mutations leading to
malignant transformation is called:
A) Apoptosis
B) Metastasis
C) Initiation-promotion-progression
D) Angiogenesis
Correct Answer: C. Initiation-promotion-progression
Rationale: Carcinogenesis involves three stages: initiation (DNA damage by carcinogen),
promotion (proliferation of initiated cells), and progression (acquisition of invasive/metastatic
capabilities). Apoptosis (A) is programmed cell death; metastasis (B) is spread to distant sites;
angiogenesis (D) is new blood vessel formation .
Question 4
A patient receiving chemotherapy develops neutropenia. Which assessment finding is most
concerning?
A) Temperature of 38.3°C (101.0°F)
B) Fatigue
,C) Nausea
D) Alopecia
Correct Answer: A. Temperature of 38.3°C (101.0°F)
Rationale: Fever in a neutropenic patient (febrile neutropenia) is a medical emergency indicating
possible sepsis. Neutropenic patients have impaired inflammatory response and may not show
typical signs of infection. Fever is the earliest sign requiring immediate evaluation and
antibiotics. Fatigue (B), nausea (C), and alopecia (D) are common but not life-threatening .
Question 5
A patient with breast cancer is receiving trastuzumab (Herceptin). This medication is most
effective in patients whose tumors are:
A) Estrogen receptor-positive
B) HER2/neu-positive
C) Triple-negative
D) Progesterone receptor-positive
Correct Answer: B. HER2/neu-positive
Rationale: Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor. It is
effective only in tumors that overexpress HER2 (HER2-positive breast cancer). Testing for
HER2 status is required before prescribing. Estrogen receptor-positive tumors are treated with
hormonal therapy (tamoxifen, aromatase inhibitors) .
Question 6
A patient receiving cisplatin reports tinnitus. What is the priority nursing action?
A) Administer acetaminophen for pain
B) Notify the provider immediately
C) Administer IV fluids to enhance excretion
D) Document the finding and continue monitoring
Correct Answer: B. Notify the provider immediately
Rationale: Cisplatin causes ototoxicity (tinnitus, hearing loss), which can be irreversible. Tinnitus
is an early sign of ototoxicity; prompt reporting may allow dose adjustment or discontinuation.
Administering fluids (C) may only help with nephrotoxicity, not ototoxicity. Documentation alone
(D) is insufficient without notifying the provider .
, Question 7
Tumor lysis syndrome (TLS) is a metabolic emergency most commonly associated with
treatment of which malignancies?
A) Solid tumors (breast, lung, colon)
B) Leukemia and lymphoma
C) Brain tumors
D) Melanoma
Correct Answer: B. Leukemia and lymphoma
Rationale: TLS occurs when tumor cells lyse rapidly after chemotherapy, releasing intracellular
contents into the bloodstream. It is most common in highly proliferative, chemotherapy-sensitive
tumors (acute leukemias, high-grade lymphomas, Burkitt lymphoma). TLS causes
hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, acute kidney injury, and
arrhythmias .
Question 8
The nurse is teaching a patient about colony-stimulating factors (filgrastim, pegfilgrastim). Which
statement indicates correct understanding?
A) "This medication will increase my platelet count."
B) "It will stimulate my bone marrow to produce more white blood cells."
C) "I will take this medication orally at home."
D) "I can expect immediate results after the first dose."
Correct Answer: B. "It will stimulate my bone marrow to produce more white blood cells."
Rationale: Filgrastim and pegfilgrastim are granulocyte colony-stimulating factors (G-CSF) that
stimulate neutrophil production. They are used to prevent or treat neutropenia. They do not
increase platelets (A); thrombopoietin agonists do that. They are given subcutaneously (not oral,
C), and results take several days (D) .
Question 9
Which statement accurately describes the role of tumor suppressor genes in carcinogenesis?
A) They promote cell division when mutated
